18 results on '"Banks, Matthew L."'
Search Results
2. Adding dopamine to the complexity of sex differences in opioid reinforcement.
- Author
-
Robinson HL and Banks ML
- Subjects
- Female, Humans, Male, Reinforcement, Psychology, Sex Characteristics, Analgesics, Opioid, Dopamine
- Published
- 2021
- Full Text
- View/download PDF
3. Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats.
- Author
-
Reiner DJ, Townsend EA, Orihuel J, Applebey SV, Claypool SM, Banks ML, Shaham Y, and Negus SS
- Subjects
- Animals, Choice Behavior physiology, Conditioning, Operant drug effects, Conditioning, Operant physiology, Drug-Seeking Behavior physiology, Extinction, Psychological drug effects, Extinction, Psychological physiology, Female, Fentanyl pharmacology, Male, Opioid-Related Disorders psychology, Pain drug therapy, Pain Measurement methods, Rats, Self Administration methods, Analgesics, Opioid administration & dosage, Choice Behavior drug effects, Drug-Seeking Behavior drug effects, Pain psychology, Pain Measurement psychology, Reinforcement, Psychology
- Abstract
Rationale and Objective: Pain-related factors increase the risk for opioid addiction, and pain may function as a negative reinforcer to increase opioid taking and seeking. However, experimental pain-related manipulations generally do not increase opioid self-administration in rodents. This discrepancy may reflect insufficient learning of pain-relief contingencies or confounding effects of pain-related behavioral impairments. Here, we determined if pairing noxious stimuli with opioid self-administration would promote pain-related reinstatement of opioid seeking or increase opioid choice over food., Methods: In Experiment 1, rats self-administered fentanyl in the presence or absence of repeated intraplantar capsaicin injections in distinct contexts to model context-specific exposure to cutaneous nociception. After capsaicin-free extinction in both contexts, we tested if capsaicin would reinstate fentanyl seeking. In Experiment 2, rats self-administered heroin after intraperitoneal (i.p.) lactic acid injections to model acute visceral inflammatory pain. After lactic acid-free extinction, we tested if lactic acid would reinstate heroin seeking. In Experiment 3, we tested if repeated i.p. lactic acid or intraplantar Complete Freund's Adjuvant (CFA; to model sustained inflammatory pain) would increase fentanyl choice over food., Results: In Experiments 1-2, neither capsaicin nor lactic acid reinstated opioid seeking after extinction, and lactic acid did not increase heroin-induced reinstatement. In Experiment 3, lactic acid and CFA decreased reinforcement rate without affecting fentanyl choice., Conclusions: Results extend the range of conditions across which pain-related manipulations fail to increase opioid seeking in rats and suggest that enhanced opioid-addiction risk in humans with chronic pain involves factors other than enhanced opioid reinforcement and relapse.
- Published
- 2021
- Full Text
- View/download PDF
4. Medications Development for Treatment of Opioid Use Disorder.
- Author
-
Townsend EA, Negus SS, and Banks ML
- Subjects
- Analgesics, Opioid administration & dosage, Buprenorphine therapeutic use, Choice Behavior, Drug Development, Evidence-Based Medicine, Humans, Methadone therapeutic use, Naltrexone therapeutic use, Narcotic Antagonists administration & dosage, Narcotic Antagonists pharmacology, Narcotics administration & dosage, Opioid-Related Disorders etiology, Receptors, Opioid, mu drug effects, Self Administration, Substance Withdrawal Syndrome prevention & control, Treatment Outcome, Analgesics, Opioid agonists, Analgesics, Opioid therapeutic use, Narcotic Antagonists therapeutic use, Narcotics agonists, Narcotics therapeutic use, Opioid-Related Disorders drug therapy, Substance Withdrawal Syndrome drug therapy
- Abstract
This review describes methods for preclinical evaluation of candidate medications to treat opioid use disorder (OUD). The review is founded on the propositions that (1) drug self-administration procedures provide the most direct method for assessment of medication effectiveness, (2) procedures that assess choice between opioid and nondrug reinforcers are especially useful, and (3) states of opioid dependence and withdrawal profoundly influence both opioid reinforcement and effects of candidate medications. Effects of opioid medications and vaccines on opioid choice in nondependent and opioid-dependent subjects are reviewed. Various nonopioid medications have also been examined, but none yet have been identified that safely and reliably reduce opioid choice. Future research will focus on (1) strategies for increasing safety and/or effectiveness of opioid medications (e.g., G-protein-biased μ-opioid agonists), and (2) continued development of nonopioid medications (e.g., clonidine) that might serve as adjunctive agents to current opioid medications., (Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
5. A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys.
- Author
-
Townsend EA, Bremer PT, Jacob NT, Negus SS, Janda KD, and Banks ML
- Subjects
- Animals, Choice Behavior drug effects, Dose-Response Relationship, Drug, Female, Food, Macaca mulatta, Male, Opioid-Related Disorders, Phylogeny, Rats, Reinforcement, Psychology, Self Administration, Analgesics, Opioid pharmacology, Feeding Behavior drug effects, Fentanyl pharmacology, Vaccines
- Abstract
Aim: Opioid-targeted vaccines are under consideration as candidate Opioid Use Disorder medications. We recently reported that a fentanyl-targeted vaccine produced a robust and long-lasting attenuation of fentanyl-vs-food choice in rats. In the current study, we evaluated an optimized fentanyl-targeted vaccine in rhesus monkeys to determine whether vaccine effectiveness to attenuate fentanyl choice translated to a species with greater phylogenetic similarity to humans., Methods: Adult male (2) and female (3) rhesus monkeys were trained to respond under a concurrent schedule of food (1 g pellets) and intravenous fentanyl (0, 0.032-1 μg/kg/injection) reinforcement during daily 2 h sessions. Fentanyl choice dose-effect functions were determined daily and 7-day buprenorphine treatments (0.0032-0.032 mg/kg/h IV; n = 4-5) were determined for comparison to vaccine effects. Subsequently, a fentanyl-CRM
197 conjugate vaccine was administered at week 0, 3, 8, 15 over a 29-week experimental period during which fentanyl choice dose-effect functions continued to be determined daily., Results: Buprenorphine significantly decreased fentanyl choice and reciprocally increased food choice. Vaccination eliminated fentanyl choice and increased food choice in four-of-the-five monkeys. A transient and less robust vaccine effect was observed in the fifth monkey. Fentanyl-specific antibody concentrations peaked after the third vaccination to approximately 50 μg/mL while anti-fentanyl antibody affinity increased to a sustained low nanomolar level., Conclusion: These results translate fentanyl vaccine effectiveness from rats to rhesus monkeys to decrease fentanyl-vs-food choice, albeit with greater individual differences observed in monkeys. These results support the potential and further clinical evaluation of this fentanyl-targeted vaccine as a candidate Opioid Use Disorder medication., (Copyright © 2020 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
6. Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys.
- Author
-
Townsend EA, Negus SS, Poklis JL, and Banks ML
- Subjects
- Animals, Choice Behavior physiology, Dose-Response Relationship, Drug, Feeding Behavior physiology, Female, Macaca mulatta, Male, Self Administration, Analgesics, Opioid administration & dosage, Benzazepines administration & dosage, Choice Behavior drug effects, Feeding Behavior drug effects, Feeding Behavior psychology, Heroin administration & dosage
- Abstract
Background: The current opioid crisis has reinvigorated preclinical research in the evaluation of non-opioid candidate treatments for opioid use disorder (OUD). Emerging evidence suggests 5-HT
2C receptor agonists may attenuate the abuse-related effects of opioids. This study evaluated effectiveness of 7-day treatment with the clinically available 5-HT2C agonist lorcaserin (Belviq®) on heroin-vs.-food choice in rhesus monkeys. Lorcaserin effects were compared to effects produced by 7-day saline substitution and by 7-day treatment with the opioid antagonist naltrexone., Methods: Adult male (1) and female (6) rhesus monkeys were trained to respond under a concurrent schedule of food delivery (1 g pellets, fixed-ratio 100 schedule) and intravenous heroin injections (0-0.032 mg/kg/injection, fixed-ratio 10 schedule) during daily 2 h sessions. Heroin choice dose-effect functions were determined daily before and following 7-day saline substitution or 7-day continuous treatment with naltrexone (0.0032-0.032 mg/kg/h, IV) or lorcaserin (0.032-0.32 mg/kg/h, IV)., Results: Under baseline conditions, increasing heroin doses maintained a dose-dependent increase in heroin choice. Both saline substitution and 7-day naltrexone treatment significantly attenuated heroin choice and produced a reciprocal increase in food choice. Continuous lorcaserin (0.32 mg/kg/h) treatment significantly increased heroin choice., Conclusions: In contrast to saline substitution and naltrexone, lorcaserin treatment was ineffective to reduce heroin-vs.-food choice. These preclinical results do not support the therapeutic potential and continued evaluation of lorcaserin as a candidate OUD treatment., Competing Interests: Declaration of Competing Interest All authors declare there are no competing financial interests or potential conflicts of interest in relation to the research described., (Copyright © 2020 Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
7. Effects of repeated kappa-opioid receptor agonist U-50488 treatment and subsequent termination on intracranial self-stimulation in male and female rats.
- Author
-
Faunce KE and Banks ML
- Subjects
- Animals, Brain, Deep Brain Stimulation, Dose-Response Relationship, Drug, Drug Tolerance, Female, Male, Rats, Rats, Sprague-Dawley, Substance Withdrawal Syndrome, Substance-Related Disorders, 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer pharmacology, Analgesics, Opioid pharmacology, Medial Forebrain Bundle, Receptors, Opioid, kappa agonists, Self Stimulation drug effects
- Abstract
Repeated drug administration results in sensitization, tolerance, or no change in subsequent drug-induced alterations of motivated behaviors, such as intracranial self-stimulation (ICSS). For example, repeated mu-opioid agonist administration results in increased expression of mu agonist-induced facilitation of ICSS. Acute kappa-opioid receptor (KOR) agonist administration depresses ICSS; however, effects of repeated KOR agonist administration on ICSS are unknown. This study determined effects of daily KOR agonist U-50488 administration and subsequent termination on ICSS in male and female rats. Female (n = 5) and male (n = 6) Sprague-Dawley rats were trained to respond for electrical brain stimulation under a frequency-rate ICSS procedure. Sequential U-50488 dose-effect functions (1-5.6 mg/kg, intraperitoneal) were determined every 7 days over a 21-day experimental period during which saline and increasing U-50488 doses (3.2-5.6 mg/kg, intraperitoneal) were administered on intervening days. Sequential U-50488 dose-effect functions were also determined 7 and 28 days after termination of repeated U-50488 administration. U-50488 dose-dependently depressed ICSS in both female and male rats. There were no sex differences on either initial or repeated U-50488 treatment effects. Repeated 5.6 mg/kg U-50488 administration produced selective tolerance to the rate-decreasing, but not threshold-altering, effects of 5.6 mg/kg U-50488 during sequential dose-effect test sessions. Neither repeated U-50488 administration nor termination of U-50488 significantly altered baseline ICSS. Overall, these results suggest neither tolerance nor sensitization develops to the depressive-like effects of repeated KOR agonist activation. Selective tolerance to the rate-decreasing effects of repeated KOR agonist administration may have implications for elucidating the neurobiological processes involved in long-term abused drug self-administration. (PsycINFO Database Record (c) 2020 APA, all rights reserved).
- Published
- 2020
- Full Text
- View/download PDF
8. Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats.
- Author
-
Townsend EA, Negus SS, Caine SB, Thomsen M, and Banks ML
- Subjects
- Animals, Dietary Sucrose administration & dosage, Female, Food, Formulated, Male, Rats, Sprague-Dawley, Reinforcement Schedule, Analgesics, Opioid administration & dosage, Choice Behavior drug effects, Fentanyl administration & dosage, Food Preferences drug effects, Reinforcement, Psychology, Sex Characteristics
- Abstract
Clinical evidence suggest that men are more sensitive than women to the abuse-related effects of mu-opioid agonists. In contrast, preclinical studies suggest the opposite sex difference. The aim of the present study was to clarify this discrepancy using a fentanyl vs. diluted Ensure
® choice procedure to assess sex differences in opioid reinforcement. Sex differences in intravenous (IV) fentanyl self-administration were examined under a fixed-ratio (FR5) schedule, a multi-day progressive-ratio (PR) schedule for behavioral economic analysis, and a concurrent (choice) schedule of fentanyl and diluted Ensure® reinforcement in Sprague-Dawley male and female rats. The fentanyl dose-effect function under the FR5 schedule was significantly shifted upward in females compared to males. Similarly, the reinforcing effectiveness of both fentanyl (3.2 and 10 µg/kg per injection, IV) and diluted Ensure® (18 and 56%) were greater in females than in males as assessed using behavioral economic analysis, irrespective of dose or concentration. However, under a fentanyl vs. foodchoice procedure, males chose 3.2 µg/kg per injection fentanyl injections over 18%, but not 56%, diluted Ensure® at a higher percentage compared to females. Overall, these results suggest that the expression of sex differences in opioid reinforcement depends upon the schedule of reinforcement and that preclinical opioid vs. food choice procedures provide a translationally relevant measure (i.e., behavioral allocation) consistent with the direction of sex differences reported in the clinical literature.- Published
- 2019
- Full Text
- View/download PDF
9. Vaccine blunts fentanyl potency in male rhesus monkeys.
- Author
-
Tenney RD, Blake S, Bremer PT, Zhou B, Hwang CS, Poklis JL, Janda KD, and Banks ML
- Subjects
- Analgesics, Opioid pharmacology, Animals, Behavior, Animal drug effects, Conditioning, Operant drug effects, Dose-Response Relationship, Drug, Fentanyl pharmacology, Macaca mulatta, Male, Naltrexone pharmacology, Narcotic Antagonists pharmacology, Nociception drug effects, Receptors, Opioid, mu, Tetanus Toxoid pharmacology, Vaccines immunology, Vaccines pharmacology, Vaccines, Conjugate pharmacology, Analgesics, Opioid immunology, Fentanyl immunology, Oxycodone pharmacology, Tetanus Toxoid immunology, Vaccines, Conjugate immunology
- Abstract
One proposed factor contributing to the increased frequency of opioid overdose deaths is the emergence of novel synthetic opioids, including illicit fentanyl and fentanyl analogues. A treatment strategy currently under development to address the ongoing opioid crisis is immunopharmacotherapies or opioid-targeted vaccines. The present study determined the effectiveness and selectivity of a fentanyl-tetanus toxoid conjugate vaccine to alter the behavioral effects of fentanyl and a structurally dissimilar mu-opioid agonist oxycodone in male rhesus monkeys (n = 3-4). Fentanyl and oxycodone produced dose-dependent suppression of behavior in an assay of schedule-controlled responding and antinociception in an assay of thermal nociception (50 °C). Acute naltrexone (0.032 mg/kg) produced an approximate 10-fold potency shift for fentanyl to decrease operant responding. The fentanyl vaccine was administered at weeks 0, 2, 4, 9, 19, and 44 and fentanyl or oxycodone potencies in both behavioral assays were redetermined over the course of 49 weeks. The vaccine significantly and selectively shifted fentanyl potency at least 10-fold in both assays at several time points over the entire experimental period. Mid-point titer levels correlated with fentanyl antinociceptive potency shifts. Antibody affinity for fentanyl as measured by a competitive binding assay improved over time to approximately 3-4 nM. The fentanyl vaccine also increased fentanyl plasma levels approximately 6-fold consistent with the hypothesis that the vaccine sequesters fentanyl in the blood. Overall, these results support the continued development and evaluation of this fentanyl vaccine in humans to address the ongoing opioid crisis., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
10. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats.
- Author
-
Townsend EA, Blake S, Faunce KE, Hwang CS, Natori Y, Zhou B, Bremer PT, Janda KD, and Banks ML
- Subjects
- Adrenergic alpha-2 Receptor Agonists pharmacology, Animals, Clonidine pharmacology, Feeding Behavior drug effects, Female, Food, Male, Naltrexone pharmacology, Narcotic Antagonists pharmacology, Opioid-Related Disorders, Rats, Reinforcement, Psychology, Self Administration, Substance Withdrawal Syndrome physiopathology, Tetanus Toxoid, Analgesics, Opioid administration & dosage, Analgesics, Opioid immunology, Behavior, Animal drug effects, Choice Behavior drug effects, Drug-Seeking Behavior drug effects, Fentanyl administration & dosage, Fentanyl immunology, Vaccines, Conjugate pharmacology
- Abstract
The current opioid crisis remains a significant public health issue and there is a critical need for biomedical research to develop effective and easily deployable candidate treatments. One emerging treatment strategy for opioid use disorder includes immunopharmacotherapies or opioid-targeted vaccines. The present study determined the effectiveness of a fentanyl-tetanus toxoid conjugate vaccine to alter fentanyl self-administration using a fentanyl-vs.-food choice procedure in male and female rats under three experimental conditions. For comparison, continuous 7-day naltrexone (0.01-0.1 mg/kg/h) and 7-day clonidine (3.2-10 μg/kg/h) treatment effects were also determined on fentanyl-vs.-food choice. Male and female rats responded for concurrently available 18% diluted Ensure® (liquid food) and fentanyl (0-10 μg/kg/infusion) infusions during daily sessions. Under baseline and saline treatment conditions, fentanyl maintained a dose-dependent increase in fentanyl-vs.-food choice. First, fentanyl vaccine administration significantly blunted fentanyl reinforcement and increased food reinforcement for 15 weeks in non-opioid dependent rats. Second, surmountability experiments by increasing the unit fentanyl dose available during the self-administration session 10-fold empirically determined that the fentanyl vaccine produced an approximate 22-fold potency shift in fentanyl-vs.-food choice that was as effective as the clinically approved treatment naltrexone. Clonidine treatment significantly increased fentanyl-vs.-food choice. Lastly, fentanyl vaccine administration prevented the expression of withdrawal-associated increases in fentanyl-vs.-food choice following introduction of extended 12 h fentanyl access sessions. Overall, these results support the potential and further consideration of immunopharmacotherapies as candidate treatments to address the current opioid crisis.
- Published
- 2019
- Full Text
- View/download PDF
11. Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.
- Author
-
Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, and Negus SS
- Subjects
- Animals, Dose-Response Relationship, Drug, Male, Medial Forebrain Bundle drug effects, Rats, Rats, Sprague-Dawley, Receptor, Serotonin, 5-HT2A drug effects, Receptors, Opioid, kappa agonists, Analgesics, Opioid pharmacology, Hallucinogens pharmacology, Self Stimulation drug effects, Serotonin 5-HT2 Receptor Agonists pharmacology
- Abstract
The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enforcement Administration. Accumulating clinical evidence has also suggested that acute or repeated "microdosing" with these drugs may have utility for treatment of some mental health disorders, including drug abuse and depression. The goal of the present study was to evaluate LSD, mescaline, and psilocybin effects on intracranial self-stimulation (ICSS), a procedure that has been used to evaluate abuse-related effects of other classes of abused drugs. Effects of repeated LSD were also examined to evaluate potential changes in its own effects on ICSS or changes in effects produced by the abused psychostimulant methamphetamine or the prodepressant kappa opioid receptor (KOR) agonist U69,593. Male Sprague-Dawley rats were implanted with microelectrodes targeting the medial forebrain bundle and trained to respond under a "frequency-rate" ICSS procedure, in which many drugs of abuse increase (or "facilitate") ICSS. In acute dose-effect and time-course studies, evidence for abuse-related ICSS facilitation was weak and inconsistent; the predominant effect of all 3 drugs was dose- and time-dependent ICSS depression. Repeated LSD treatment failed to alter either its own ICSS depressant effects or the abuse-related effects of methamphetamine; however, repeated LSD did attenuate ICSS depression by U69,593. These results extend those of previous preclinical studies to suggest weak expression of abuse-related effects by 5-HT2A agonist hallucinogens and provide supportive evidence for therapeutic effects of repeated LSD dosing to attenuate KOR-mediated depressant effects but not abuse potential of psychostimulants. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
- Published
- 2019
- Full Text
- View/download PDF
12. Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
- Author
-
Cornelissen JC, Steele FF, Tenney RD, Obeng S, Rice KC, Zhang Y, and Banks ML
- Subjects
- Animals, Macaca mulatta, Male, Analgesics, Opioid therapeutic use, Imidazoles therapeutic use, Opioid Peptides therapeutic use, Pain drug therapy, Receptors, Opioid agonists, Spiro Compounds therapeutic use
- Abstract
Mu-opioid receptor agonists are clinically effective analgesics, but also produce undesirable effects that limit their clinical utility. The nociceptin opioid peptide (NOP) receptor system also modulates nociception, and NOP agonists might be useful adjuncts to enhance the analgesic effects or attenuate the undesirable effects of mu-opioid agonists. The present study determined behavioral interactions between the NOP agonist (-)-Ro 64-6198 and mu-opioid ligands that vary in mu-opioid receptor efficacy (17-cyclopropylmethyl-3,14β-dihyroxy-4,5α-epoxy-6α-[(3 ́-isoquinolyl)acetamindo]morphinan (NAQ) < buprenorphine < nalbuphine < morphine = oxycodone < methadone) in male rhesus monkeys. For comparison, Ro 64-6198 interactions were also examined with the kappa-opioid receptor agonist nalfurafine. Each opioid ligand was examined alone and following fixed-dose Ro 64-6198 pretreatments in assays of thermal nociception (n = 3-4) and schedule-controlled responding (n = 3). Ro 64-6198 alone failed to produce significant antinociception up to doses (0.32 mg/kg, IM) that significantly decreased rates of responding. All opioid ligands, except NAQ and nalfurafine, produced dose- and thermal intensity-dependent antinociception. Ro 64-6198 enhanced the antinociceptive potency of buprenorphine, nalbuphine, methadone, and nalfurafine. Ro 64-6198 enhancement of nalbuphine antinociception was NOP antagonist SB-612111 reversible and occurred under a narrow range of dose and time conditions. All opioid ligands, except NAQ and buprenorphine, produced dose-dependent decreases in rates of responding. Ro 64-6198 did not significantly alter mu-opioid ligand rate-decreasing effects. Although these results suggest that NOP agonists may selectively enhance the antinociceptive vs. rate-suppressant effects of some mu-opioid agonists, this small enhancement occurred under a narrow range of conditions dampening enthusiasm for NOP agonists as candidate "opioid-sparing" adjuncts., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
13. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
- Author
-
Wilkerson JL, Niphakis MJ, Grim TW, Mustafa MA, Abdullah RA, Poklis JL, Dewey WL, Akbarali H, Banks ML, Wise LE, Cravatt BF, and Lichtman AH
- Subjects
- Animals, Arachidonic Acids metabolism, Behavior, Animal drug effects, Constriction, Pathologic complications, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Synergism, Endocannabinoids metabolism, Glycerides metabolism, Hyperalgesia chemically induced, Hyperalgesia drug therapy, Male, Mice, Mice, Inbred C57BL, Morphine administration & dosage, Morphine therapeutic use, Neuralgia chemically induced, Neuralgia psychology, Receptor, Cannabinoid, CB1 drug effects, Receptor, Cannabinoid, CB2 drug effects, Receptors, Opioid, mu drug effects, Analgesics, Opioid therapeutic use, Carbamates pharmacology, Enzyme Inhibitors pharmacology, Monoacylglycerol Lipases antagonists & inhibitors, Neuralgia drug therapy, Succinimides pharmacology
- Abstract
Serious clinical liabilities associated with the prescription of opiates for pain control include constipation, respiratory depression, pruritus, tolerance, abuse, and addiction. A recognized strategy to circumvent these side effects is to combine opioids with other antinociceptive agents. The combination of opiates with the primary active constituent of cannabis (Δ(9)-tetrahydrocannabinol) produces enhanced antinociceptive actions, suggesting that cannabinoid receptor agonists can be opioid sparing. Here, we tested whether elevating the endogenous cannabinoid 2-arachidonoylglycerol through the inhibition of its primary hydrolytic enzyme monoacylglycerol lipase (MAGL), will produce opioid-sparing effects in the mouse chronic constriction injury (CCI) of the sciatic nerve model of neuropathic pain. The dose-response relationships of i.p. administration of morphine and the selective MAGL inhibitor 2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate (MJN110) were tested alone and in combination at equieffective doses for reversal of CCI-induced mechanical allodynia and thermal hyperalgesia. The respective ED50 doses (95% confidence interval) of morphine and MJN110 were 2.4 (1.9-3.0) mg/kg and 0.43 (0.23-0.79) mg/kg. Isobolographic analysis of these drugs in combination revealed synergistic antiallodynic effects. Acute antinociceptive effects of the combination of morphine and MJN110 required μ-opioid, CB1, and CB2 receptors. This combination did not reduce gastric motility or produce subjective cannabimimetic effects in the drug discrimination assay. Importantly, combinations of MJN110 and morphine given repeatedly (i.e., twice a day for 6 days) continued to produce antiallodynic effects with no evidence of tolerance. Taken together, these findings suggest that MAGL inhibition produces opiate-sparing events with diminished tolerance, constipation, and cannabimimetic side effects., (Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2016
- Full Text
- View/download PDF
14. Medications development for opioid abuse.
- Author
-
Negus SS and Banks ML
- Subjects
- Analgesics, Opioid administration & dosage, Buprenorphine therapeutic use, Choice Behavior, Endocannabinoids therapeutic use, Evidence-Based Medicine, Humans, Methadone therapeutic use, Naltrexone therapeutic use, Narcotic Antagonists administration & dosage, Narcotic Antagonists pharmacology, Narcotics administration & dosage, Neuroglia drug effects, Opioid-Related Disorders etiology, Reinforcement, Psychology, Self Administration, Substance Withdrawal Syndrome prevention & control, Treatment Outcome, Analgesics, Opioid agonists, Analgesics, Opioid therapeutic use, Narcotic Antagonists therapeutic use, Narcotics agonists, Narcotics therapeutic use, Opioid-Related Disorders drug therapy, Receptors, Opioid, mu drug effects, Substance Withdrawal Syndrome drug therapy
- Abstract
Here we describe methods for preclinical evaluation of candidate medications to treat opioid abuse and dependence. Our perspective is founded on the propositions that (1) drug self-administration procedures provide the most direct method for assessment of medication effects, (2) procedures that assess choice between opioid and nondrug reinforcers are especially useful, and (3) the states of opioid dependence and withdrawal profoundly influence both opioid reinforcement and the effects of candidate medications. Effects of opioid medications on opioid choice in nondependent and opioid-dependent subjects are reviewed. Various nonopioid medications have also been examined, but none yet have been identified that safely and reliably reduce opioid choice. Future research will focus on (1) strategies for increasing safety and/or effectiveness of opioid medications, and (2) continued development of nonopioids such as inhibitors of endocannabinoid catabolic enzymes or inhibitors of opioid-induced glial activation.
- Published
- 2013
- Full Text
- View/download PDF
15. Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys.
- Author
-
Yekkirala AS, Banks ML, Lunzer MM, Negus SS, Rice KC, and Portoghese PS
- Subjects
- Analgesics chemistry, Analgesics, Opioid chemistry, Animals, Calcium Signaling drug effects, Data Interpretation, Statistical, Female, Fentanyl administration & dosage, Fentanyl pharmacology, HEK293 Cells, Humans, Injections, Spinal, Macaca mulatta, Male, Methadone administration & dosage, Methadone pharmacology, Mice, Naltrexone administration & dosage, Naltrexone analogs & derivatives, Naltrexone pharmacology, Narcotic Antagonists administration & dosage, Narcotic Antagonists pharmacology, Pain Measurement drug effects, Analgesics pharmacology, Analgesics, Opioid pharmacology, Receptors, Opioid, delta drug effects, Receptors, Opioid, mu drug effects
- Abstract
Morphine and related drugs are widely employed as analgesics despite the side effects associated with their use. Although morphine is thought to mediate analgesia through mu opioid receptors, delta opioid receptors have been implicated in mediating some side effects such as tolerance and dependence. Here we present evidence in rhesus monkeys that morphine, fentanyl, and possibly methadone selectively activate mu-delta heteromers to produce antinociception that is potently antagonized by the delta opioid receptor antagonist, naltrindole (NTI). Studies with HEK293 cells expressing mu-delta heteromeric opioid receptors exhibit a similar antagonism profile of receptor activation in the presence of NTI. In mice, morphine was potently inhibited by naltrindole when administered intrathecally, but not intracerebroventricularly, suggesting the possible involvement of mu-delta heteromers in the spinal cord of rodents. Taken together, these results strongly suggest that, in primates, mu-delta heteromers are allosterically coupled and mediate the antinociceptive effects of three clinically employed opioid analgesics that have been traditionally viewed as mu-selective. Given the known involvement of delta receptors in morphine tolerance and dependence, our results implicate mu-delta heteromers in mediating both antinociception and these side effects in primates. These results open the door for further investigation in humans.
- Published
- 2012
- Full Text
- View/download PDF
16. Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.
- Author
-
Banks ML, Folk JE, Rice KC, and Negus SS
- Subjects
- Animals, Conditioning, Operant drug effects, Dose-Response Relationship, Drug, Drug Synergism, Hot Temperature, Macaca mulatta, Male, Reinforcement Schedule, Analgesics, Opioid pharmacology, Anesthetics, Dissociative pharmacology, Benzamides pharmacology, Fentanyl pharmacology, Ketamine pharmacology, Piperazines pharmacology, Receptors, Opioid, delta agonists, Receptors, Opioid, mu drug effects
- Abstract
Mu-opioid receptor agonists such as fentanyl are effective analgesics, but their clinical use is limited by untoward effects. Adjunct medications may improve the effectiveness and/or safety of opioid analgesics. This study compared interactions between fentanyl and either the noncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine or the delta-opioid receptor agonist SNC162 [(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-phenyl)methyl]-N,N-diethylbenzamide] in two behavioral assays in rhesus monkeys. An assay of thermal nociception evaluated tail-withdrawal latencies from water heated to 50 and 54°C. An assay of schedule-controlled responding evaluated response rates maintained under a fixed-ratio 30 schedule of food presentation. Effects of each drug alone and of three mixtures of ketamine+fentanyl (22:1, 65:1, 195:1 ketamine/fentanyl) or SNC162+fentanyl (59:1, 176:1, 528:1 SNC162/fentanyl) were evaluated in each assay. All drugs and mixtures dose-dependently decreased rates of food-maintained responding, and drug proportions in the mixtures were based on relative potencies in this assay. Ketamine and SNC162 were inactive in the assay of thermal antinociception, but fentanyl and all mixtures produced dose-dependent antinociception. Drug interactions were evaluated using dose-addition and dose-ratio analysis. Dose-addition analysis revealed that interactions for all ketamine/fentanyl mixtures were additive in both assays. SNC162/fentanyl interactions were usually additive, but one mixture (176:1) produced synergistic antinociception at 50°C. Dose-ratio analysis indicated that ketamine failed to improve the relative potency of fentanyl to produce antinociception vs. rate suppression, whereas two SNC162/fentanyl mixtures (59:1 and 176:1) increased the relative potency of fentanyl to produce antinociception. These results suggest that delta agonists may produce more selective enhancement than ketamine of mu agonist-induced antinociception., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
17. Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy.
- Author
-
Banks ML, Rice KC, and Negus SS
- Subjects
- Analgesics, Opioid administration & dosage, Analgesics, Opioid pharmacology, Animals, Behavior, Animal drug effects, Clomipramine administration & dosage, Clomipramine pharmacology, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Synergism, Drug Therapy, Combination, Macaca mulatta, Male, Pain metabolism, Selective Serotonin Reuptake Inhibitors administration & dosage, Selective Serotonin Reuptake Inhibitors pharmacology, Analgesics, Opioid therapeutic use, Clomipramine therapeutic use, Pain drug therapy, Receptors, Opioid, mu agonists, Selective Serotonin Reuptake Inhibitors therapeutic use
- Abstract
Mu-opioid agonists are effective analgesics but have undesirable effects such as sedation and abuse liability that limit their clinical effectiveness. Serotonergic systems also modulate nociception, and serotonin uptake inhibitors may be useful as adjuncts to enhance analgesic effects and/or attenuate undesirable effects of mu agonists. This study examined the effects of the serotonin uptake inhibitor clomipramine on behavioral effects produced in rhesus monkeys by mu agonists with varying efficacy at mu receptors (nalbuphine < morphine < methadone). Clomipramine and each mu agonist were studied alone and in fixed-proportion mixtures in assays of schedule-controlled responding, thermal nociception, and capsaicin-induced thermal allodynia. In the assay of schedule-controlled responding, all mu agonists dose-dependently decreased response rates. Clomipramine was inactive alone and did not alter the effects of mu agonists. In the assay of thermal nociception, all mu agonists produced dose-dependent antinociception. Clomipramine was inactive alone but produced a proportion-dependent enhancement of the antinociceptive effects of nalbuphine > morphine > methadone. In the assay of capsaicin-induced allodynia, nalbuphine produced dose-dependent antiallodynia. Clomipramine alone was inactive, but as in the assay of thermal nociception, it produced a proportion-dependent enhancement in the effects of nalbuphine. These findings suggest that serotonin uptake inhibitors can selectively enhance the antinociceptive effects of mu agonists in nonhuman primates. These effects of serotonin uptake inhibitors may depend on the proportion of the serotonin uptake inhibitor and the efficacy of the mu agonist. The greatest enhancement was observed with intermediate proportions of clomipramine in combination with the low-efficacy mu agonist nalbuphine.
- Published
- 2010
- Full Text
- View/download PDF
18. Further Evaluation of Delta Opioid Agonists as Candidate Adjuncts to Mu Opioid Analgesics: A Comparison of Interactions between Fentanyl and either Ketamine or the Delta Agonist SNC162 in Rhesus Monkeys
- Author
-
Banks, Matthew L., Folk, John E., Rice, Kenner C., and Negus, S. Stevens
- Subjects
Male ,Anesthetics, Dissociative ,Hot Temperature ,Reinforcement Schedule ,Dose-Response Relationship, Drug ,Receptors, Opioid, mu ,Drug Synergism ,Macaca mulatta ,Article ,Piperazines ,Analgesics, Opioid ,Fentanyl ,Receptors, Opioid, delta ,Benzamides ,Animals ,Conditioning, Operant ,Ketamine - Abstract
Mu-opioid receptor agonists such as fentanyl are effective analgesics, but their clinical use is limited by untoward effects. Adjunct medications may improve the effectiveness and/or safety of opioid analgesics. This study compared interactions between fentanyl and either the noncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine or the delta-opioid receptor agonist SNC162 [(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-phenyl)methyl]-N,N-diethylbenzamide] in two behavioral assays in rhesus monkeys. An assay of thermal nociception evaluated tail-withdrawal latencies from water heated to 50 and 54°C. An assay of schedule-controlled responding evaluated response rates maintained under a fixed-ratio 30 schedule of food presentation. Effects of each drug alone and of three mixtures of ketamine +fentanyl (22:1, 65:1, 195:1 ketamine/fentanyl) or SNC162+fentanyl (59:1, 176:1, 528:1 SNC162/fentanyl) were evaluated in each assay. All drugs and mixtures dose-dependently decreased rates of food-maintained responding, and drug proportions in the mixtures were based on relative potencies in this assay. Ketamine and SNC162 were inactive in the assay of thermal antinociception, but fentanyl and all mixtures produced dose-dependent antinociception. Drug interactions were evaluated using dose-addition and dose-ratio analysis. Dose-addition analysis revealed that interactions for all ketamine/fentanyl mixtures were additive in both assays. SNC162/fentanyl interactions were usually additive, but one mixture (176:1) produced synergistic antinociception at 50°C. Dose-ratio analysis indicated that ketamine failed to improve the relative potency of fentanyl to produce antinociception vs. rate suppression, whereas two SNC162/fentanyl mixtures (59:1 and 176:1) increased the relative potency of fentanyl to produce antinociception. These results suggest that delta agonists may produce more selective enhancement than ketamine of mu agonist-induced antinociception.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.